CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 24, 2006--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced that Amgen, Inc. and certain affiliated entities have filed an action in the United States District Court for the District of Delaware seeking a declaratory judgment that each of the claims contained in U.S. Patent No. 6,410,516 (the "'516 Patent") covering methods of treating human disease by regulating NF-(kappa)B cell-signaling activity are invalid and that Amgen and its affiliated entities have not infringed any claims of the '516 Patent based on activities related to the products, Enbrel® and Kineret®.
